Anticancer research · 2014
A Long-term follow-up study of 91 cases with ovarian granulosa cell tumors.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shim Seung-Hyuk, Lee Sun Joo, Kim Dae-Yeon, Kim Jin, Kim Soo-Nyung, Kang Soon-Beom, Kim Jong-Hyeok, Kim Yong-Man, Kim Young-Tak, Nam Joo-Hyun
Аннотация
AIM: To evaluate the prognostic factors of ovarian granulosa cell tumors (GCTs) and treatment outcomes in recurrent GCT cases.
PATIENTS AND METHODS: We retrospectively reviewed 91 patients with GCT who were treated in two tertiary Centers between 1989 and 2011.
RESULTS: Eighty patients had stage I tumors, five had stage II, and six had stage III. There were 15 cases of recurrence with a median follow-up time of 58 (3-254) months. Multivariate analysis identified greater tumor size and postoperative residual tumor as independent risk factors for recurrence. Twelve patients underwent secondary surgery at first recurrence. At a median follow-up of 50 (4-185) months from first recurrence, the 5-year survival was 60% for patients with and 100% for those without residual tumor after secondary surgery, respectively (p=0.018, log-rank test).
CONCLUSION: Complete cytoreduction is an important prognostic factor for recurrent cases as well as initial treatment of GCT.
PATIENTS AND METHODS: We retrospectively reviewed 91 patients with GCT who were treated in two tertiary Centers between 1989 and 2011.
RESULTS: Eighty patients had stage I tumors, five had stage II, and six had stage III. There were 15 cases of recurrence with a median follow-up time of 58 (3-254) months. Multivariate analysis identified greater tumor size and postoperative residual tumor as independent risk factors for recurrence. Twelve patients underwent secondary surgery at first recurrence. At a median follow-up of 50 (4-185) months from first recurrence, the 5-year survival was 60% for patients with and 100% for those without residual tumor after secondary surgery, respectively (p=0.018, log-rank test).
CONCLUSION: Complete cytoreduction is an important prognostic factor for recurrent cases as well as initial treatment of GCT.